PRESCRIBING INFORMATION: (Refer to Summary of Product Characteristics before prescribing)

CERVARIX® Human Papillomavirus Vaccine (HPV) [Types 16, 18]). **Active ingredients:** Each 0.5 ml dose contains: HPV 16 L1 protein 20 mcg, HPV 18 L1 protein 20 mcg, adjuvanted by AS04, adsorbed on aluminium hydroxide **Indication:** For prevention of premalignant ano-genital lesions and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. **Dosage information**: By i.m injection into the deltoid region. From 9 to 14 years: 0.5 ml suspension at 0 and 5-13 months. From 15 years, 0.5 ml at 0, 1 (1-2.5), and 6 (5-12) months. Subjects receiving a first dose of Cervarix should complete the vaccination course with Cervarix. **Adverse reactions:** See SPC for full details. Common**:** headache, GI symptoms, pruritis, rash, urticaria, myalgia, arthralgia, fatigue, local injection site reactions, fever, Serious: Allergic reactions including anaphylactic/anaphylactoid reactions and angioedema, syncope accompanied by neurological signs such as visual disturbance paraesthesia, and tonic-clonic limb movement. **Contraindications:** Hypersensitivity to the active substances or to any of the excipients. **Precautions and warnings:** Administration of Cervarix should be postponed in subjects suffering from an acute severe febrile illness. However, the presence of a minor infection, such as a cold, is not a contraindication for immunisation. Caution in thrombocytopenia or coagulation disorder. Protective immune response may not be elicited in all vaccinees e.g. immunocompromised. If pregnant or trying to become pregnant, postpone or interrupt vaccination until completion of pregnancy. Consider risk/benefit of use while breast-feeding. **Legal category:** POM **Cost:** Pre-filled 0.5 ml syringe NHS cost £80.50. **MA number** EU/1/07/419/004-9. **MA holder:** GlaxoSmithKline Biologicals s.a. Rue de l'Institut 89, B-1330 Rixensart, Belgium. **For further information in the UK, please contact the GSK Customer Contact Centre: customercontactuk@gsk.com, freephone 0800 221 441.**

PI-0504 (V2.0)
Date of preparation: November 2020

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline 0800 221 441